Interclean Shanghai

Elevating UK Healthcare With Ethical AI Solutions By BSI

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

EU Begins Revision of Medical Device...

The European Commission has gone on to initiate a...

FDA Seeks Opinion on AI-Enabled Medical...

The U.S. Food and Drug Administration (US FDA) is...

FDA Approves Zenix Monitor-Defibrillator from ZOLL

ZOLL®, which happens to be an Asahi Kasei company...

MHRA in the UK Accelerates AI...

The Medicines and Healthcare Products Regulatory Agency (MHRA) from...

With the emergence of advanced AI tools, healthcare practitioners and providers in the UK have the opportunity to make well-informed diagnostic decisions efficiently, leading to improved disease intervention, prevention, and treatment. This advancement holds the potential to enhance patients’ quality of life and contribute positively to society.

Amidst the ongoing global discourse about the appropriate integration of AI, a Validation framework tailored for the application of AI in the UK’s healthcare sector, known as Specification (BS 30440), is being introduced. Its primary objective is to enhance confidence among UK-based clinicians, healthcare professionals, and clinical providers regarding the safe, effective, and ethical development of the AI tools they employ. This auditable standard, designed for global relevance, specifically focuses on products primarily intended for the treatment, diagnosis, or management of health conditions in the UK.

Projections suggest that the worldwide healthcare AI market could exceed $187.95 billion by 2030. Nevertheless, healthcare practitioners and providers in the UK might face constraints in terms of time, resources, or internal capacity to thoroughly assess AI products. In this context, the specification serves as a tool for making informed decisions regarding the adoption of AI tools. It facilitates the evaluation of healthcare AI products by both UK-based clinicians and patients, considering factors such as clinical utility, performance standards, integration into local clinical workflows, ethical considerations, and equitable societal outcomes.

This framework encompasses a diverse range of healthcare AI products used within various UK settings. It encompasses regulated medical devices (such as medical software), products directly accessed by users (e.g., imaging software), or those used by patients (like AI-driven smartphone chatbots). Furthermore, it extends to AI products used in home-based or community care settings, covering a wide array of products, models, systems, or technologies incorporating AI elements, including machine learning. The specification’s relevance extends beyond AI system suppliers and product auditors; it has been meticulously crafted by a multidisciplinary team of UK-based experts, including clinicians, AI specialists, ethicists, and healthcare leaders. It consolidates existing guidance and best practices, translating intricate functionality assessments into a structured framework against which AI systems can be evaluated.

For organizations operating within the UK’s healthcare sector and all those engaged with it, this standard holds profound significance. As AI gains prominence and showcases its potential to revolutionize healthcare within the UK, this framework will play a pivotal role in ensuring the responsible and ethical utilization of AI tools. Through the application of innovative AI tools and algorithms adept at processing substantial data volumes, clinicians and healthcare providers in the UK can make prompt and accurate well-informed diagnostic decisions, ultimately leading to more effective disease management and an enhanced quality of life for patients.

This specification effectively addresses the pressing need for an established validation framework for AI development and clinical assessment within the UK’s healthcare landscape. It builds upon a foundation initially tested by experts at Guy’s and St. Thomas Cancer Centre within the UK, refined through ongoing consultations with UK-based stakeholders entrenched in the AI and Machine Learning domain. Concurrently, the British Standards Institution (BSI) has been collaborating with UK regulators, healthcare institutions, and other relevant bodies to explore the role of standards in regulating and overseeing AI within the UK’s healthcare sector.

Latest stories

Related stories

EU Begins Revision of Medical Device Regulatory Framework

The European Commission has gone on to initiate a...

FDA Seeks Opinion on AI-Enabled Medical Devices Regulation

The U.S. Food and Drug Administration (US FDA) is...

FDA Approves Zenix Monitor-Defibrillator from ZOLL

ZOLL®, which happens to be an Asahi Kasei company...

MHRA in the UK Accelerates AI Rollout in the NHS

The Medicines and Healthcare Products Regulatory Agency (MHRA) from...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »